CohBar, Inc.: insider trades · United States · SEC (Form 4)

About CohBar, Inc.

CohBar, Inc. is a U.S.-listed biopharmaceutical company that historically traded on the NASDAQ under the ticker CWBR and was based in Menlo Park, California, United States. Founded in 2007, the company was built around a highly specialized scientific thesis: using mitochondrial-derived peptides and mitochondria-based biology to discover potential therapies for chronic, inflammatory, metabolic, and age-related diseases. In that sense, CohBar belongs to the small-cap biotech universe where valuation is driven primarily by the strength of the platform, the quality of the intellectual property portfolio, and the ability to advance programs toward clinical proof of concept, rather than by current revenue generation. CohBar’s core business model has centered on a discovery engine known as MITO+, designed to identify and optimize peptide analogs derived from the mitochondrial genome. This platform-oriented approach positioned the company as a research-driven developer of novel therapeutics, with a pipeline that historically included preclinical and early-stage candidates rather than commercial products. For investors, that matters because the company’s economics have typically reflected the profile of a development-stage biotech: heavy R&D dependence, recurring capital needs, dilution risk, and a binary sensitivity to clinical and strategic milestones. The most important recent corporate event was CohBar’s 2023 merger agreement with Morphogenesis. Public filings and company releases indicated that the combined entity was expected to operate as TuHURA Biosciences and pursue a NASDAQ listing, signaling a major strategic pivot away from CohBar’s standalone legacy structure. Those disclosures also showed that CohBar had suspended development activities, underscoring that the company was no longer functioning as a conventional independent biotech with an active late-stage pipeline. Instead, it was transitioning into a transaction-driven situation where merger execution, financing structure, and post-deal strategic direction became the key investment variables. From a competitive standpoint, CohBar was a niche science company rather than a broad-based pharmaceutical competitor. Its differentiated angle was mitochondrial peptide biology, a relatively uncommon therapeutic approach compared with mainstream small molecules, antibodies, or RNA-based platforms. That differentiation could create optionality, but it also implied substantial scientific and execution risk. Geographically, the company’s principal operations were centered in California, while its investor-facing identity remained clearly U.S.-listed and NASDAQ-oriented. For French, Belgian, and Swiss investors, the stock should be viewed as a high-risk U.S. micro-cap biotech story with a legacy platform, limited operating maturity, and major corporate-action sensitivity. In practical terms, the key items to monitor are SEC filings, insider transactions reported on Form 4, and any updates on merger completion, capital structure, or post-merger listing status.